Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ODC-siRNA
- Development stage
- Preclinical
- Lead developer
- Santa Cruz Biotechnology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
ODC-siRNA is a small interfering RNA (siRNA) designed to silence the expression of ornithine decarboxylase (ODC), the rate-limiting enzyme in the polyamine biosynthetic pathway. Polyamines are essential for cell growth and proliferation, and ODC is frequently overexpressed in various cancers, including melanoma. By targeting ODC mRNA for degradation via the RNA interference (RNAi) pathway, ODC-siRNA inhibits polyamine synthesis, leading to growth arrest and apoptosis in tumor cells. In preclinical studies, ODC-siRNA has demonstrated significant growth inhibitory effects on human melanoma cell lines, particularly when used in combination with other inhibitors like mTOR inhibitors (e.g., rapamycin).
- Other names
- ornithine decarboxylase siRNAsiRNA targeting ODC
02
Targets
ODC1 (Ornithine decarboxylase)
Beyond the preview
Go deeper on ODC-siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ODC-siRNA.